News & Events

Wir bei HVD Life Sciences arbeiten mit branchenweit führenden Herstellern zusammen, um eine breite Palette hochwertiger Produkte anzubieten, die unsere Kunden befähigen, Fortschritte in der Wissenschaft zu erreichen.

Shown below is the entire HVD Life Sciences portfolio. For more specific information, select your country of residence and/or the area of interest.

Shown below is the entire HVD Life Sciences portfolio for Austria. For more specific information, select your  area of interest.


Based on 10+ years’ thorough experience and innovation research, Poietis has developed NGB-R™, a 4th generation multi-modal bioprinter based on unique laser-assisted bioprinting (LAB) technology.

Poietis brings two bioprinters based on Next-Generation Bioprinting platform to the market. NGB-R™ Bioprinter is commercialized for research applications.
NGB-C™ Bioprinter is a clinical-grade, GMP-compliant system dedicated to clinical applications and meet the requirements of translational research and challenges of industrial manufacturing of implantable tissues.

The NGB-R™ Bioprinter represents a revolutionary leap in bioprinting technology, offering unparalleled precision and flexibility for researchers in the fields of tissue engineering and regenerative medicine. Its state-of-the-art capabilities including Multimodality- Bioprinting Technology, patented LAB (Laser Assisted Bioprinting) Technology, In-Line Imaging, Zebr4D AI- assisted software etc., enable the production of complex, three-dimensional tissues to mimic the natural composition and functionality of human organs.

Founded in 2014 as a spin-off from INSERM and the University of Bordeaux, Poietis’ mission is to provide solutions leveraging its proprietary next-generation bioprinting (NGB) platform and bring tissue engineering therapies to patients.